 Brigitte Frohnert
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 48 | 2026 | 3910 | 3.370 |
Why?
| | Islets of Langerhans | 21 | 2026 | 842 | 2.720 |
Why?
| | Autoimmunity | 23 | 2026 | 930 | 2.320 |
Why?
| | Autoantibodies | 29 | 2025 | 1505 | 1.580 |
Why?
| | Celiac Disease | 5 | 2022 | 309 | 0.850 |
Why?
| | Genetic Predisposition to Disease | 11 | 2023 | 2350 | 0.850 |
Why?
| | Protein Carbonylation | 3 | 2015 | 57 | 0.820 |
Why?
| | Insulins | 1 | 2023 | 38 | 0.740 |
Why?
| | Insulin Resistance | 6 | 2013 | 1241 | 0.710 |
Why?
| | Oxidative Stress | 3 | 2013 | 1338 | 0.690 |
Why?
| | Child, Preschool | 29 | 2026 | 11790 | 0.620 |
Why?
| | Adipocytes | 4 | 2013 | 223 | 0.600 |
Why?
| | Child | 43 | 2026 | 22600 | 0.600 |
Why?
| | Insulin Infusion Systems | 3 | 2023 | 477 | 0.570 |
Why?
| | Bone Density | 3 | 2020 | 484 | 0.540 |
Why?
| | HLA-D Antigens | 1 | 2017 | 30 | 0.520 |
Why?
| | Insulin | 9 | 2023 | 2502 | 0.520 |
Why?
| | Hypoglycemic Agents | 5 | 2026 | 1388 | 0.490 |
Why?
| | Disease Progression | 11 | 2026 | 2847 | 0.470 |
Why?
| | Infusions, Subcutaneous | 1 | 2015 | 24 | 0.460 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2013 | 154 | 0.450 |
Why?
| | Infant | 19 | 2026 | 10023 | 0.440 |
Why?
| | Equipment Failure | 1 | 2015 | 115 | 0.440 |
Why?
| | Genotype | 8 | 2026 | 1847 | 0.440 |
Why?
| | Prospective Studies | 15 | 2026 | 7994 | 0.430 |
Why?
| | Models, Genetic | 1 | 2017 | 531 | 0.430 |
Why?
| | Adolescent | 28 | 2026 | 22409 | 0.420 |
Why?
| | Blood Glucose | 5 | 2026 | 2326 | 0.410 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2025 | 699 | 0.400 |
Why?
| | Lipid Peroxidation | 1 | 2013 | 163 | 0.370 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2020 | 2137 | 0.370 |
Why?
| | Humans | 63 | 2026 | 144667 | 0.370 |
Why?
| | DNA Methylation | 3 | 2023 | 664 | 0.350 |
Why?
| | Adiposity | 3 | 2013 | 529 | 0.350 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 15 | 0.340 |
Why?
| | Biomarkers | 5 | 2023 | 4261 | 0.330 |
Why?
| | Fasting | 2 | 2010 | 275 | 0.320 |
Why?
| | Case-Control Studies | 10 | 2023 | 3603 | 0.320 |
Why?
| | Obesity | 3 | 2013 | 3070 | 0.310 |
Why?
| | Metabolomics | 1 | 2015 | 724 | 0.300 |
Why?
| | Male | 38 | 2026 | 72431 | 0.300 |
Why?
| | Female | 39 | 2026 | 78304 | 0.290 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2019 | 48 | 0.280 |
Why?
| | Cystic Fibrosis | 3 | 2012 | 1166 | 0.250 |
Why?
| | Mitochondria | 1 | 2013 | 984 | 0.240 |
Why?
| | Inflammation | 2 | 2017 | 2870 | 0.230 |
Why?
| | Glucose Tolerance Test | 4 | 2026 | 360 | 0.230 |
Why?
| | Macrophages | 1 | 2013 | 1496 | 0.230 |
Why?
| | HLA Antigens | 1 | 2026 | 235 | 0.220 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2573 | 0.220 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 967 | 0.210 |
Why?
| | Oxylipins | 2 | 2023 | 47 | 0.210 |
Why?
| | HLA-DR4 Antigen | 3 | 2021 | 74 | 0.210 |
Why?
| | HLA-DR3 Antigen | 3 | 2021 | 76 | 0.210 |
Why?
| | Cardiovascular Diseases | 2 | 2013 | 2172 | 0.200 |
Why?
| | Membrane Transport Proteins | 3 | 1999 | 153 | 0.200 |
Why?
| | Carrier Proteins | 4 | 2000 | 733 | 0.190 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 220 | 0.190 |
Why?
| | GTP-Binding Proteins | 2 | 2021 | 153 | 0.190 |
Why?
| | Vitamin D | 1 | 2026 | 400 | 0.190 |
Why?
| | Transglutaminases | 2 | 2021 | 159 | 0.190 |
Why?
| | Technology | 1 | 2023 | 95 | 0.190 |
Why?
| | Glutathione Transferase | 2 | 2013 | 96 | 0.180 |
Why?
| | Growth Charts | 1 | 2022 | 20 | 0.180 |
Why?
| | Risk Factors | 11 | 2025 | 10796 | 0.180 |
Why?
| | Longitudinal Studies | 5 | 2022 | 2942 | 0.170 |
Why?
| | Young Adult | 8 | 2026 | 14122 | 0.170 |
Why?
| | Body Height | 1 | 2022 | 199 | 0.160 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2021 | 37 | 0.160 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 38 | 0.160 |
Why?
| | Prediabetic State | 1 | 2023 | 247 | 0.160 |
Why?
| | Cohort Studies | 6 | 2026 | 5957 | 0.160 |
Why?
| | Glutamate Decarboxylase | 4 | 2022 | 165 | 0.160 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.150 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 83 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2026 | 990 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 118 | 0.150 |
Why?
| | Glucose Intolerance | 2 | 2010 | 142 | 0.150 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 61 | 0.140 |
Why?
| | Butyrates | 1 | 2019 | 66 | 0.140 |
Why?
| | Insulin-Secreting Cells | 1 | 2023 | 390 | 0.140 |
Why?
| | Fibrinogen | 1 | 2019 | 181 | 0.140 |
Why?
| | Membrane Proteins | 3 | 1999 | 1159 | 0.140 |
Why?
| | Ascorbic Acid | 1 | 2019 | 171 | 0.140 |
Why?
| | Fatty Acids | 3 | 2000 | 454 | 0.140 |
Why?
| | Thiazolidinediones | 1 | 1999 | 139 | 0.140 |
Why?
| | Mentors | 1 | 2020 | 214 | 0.130 |
Why?
| | Mammals | 1 | 2000 | 296 | 0.130 |
Why?
| | Mass Spectrometry | 1 | 2021 | 743 | 0.130 |
Why?
| | Interprofessional Relations | 1 | 2020 | 275 | 0.130 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 5870 | 0.130 |
Why?
| | Discriminant Analysis | 1 | 2017 | 35 | 0.130 |
Why?
| | Triglycerides | 1 | 2000 | 517 | 0.130 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 204 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 164 | 0.130 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 276 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 236 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 613 | 0.120 |
Why?
| | Models, Statistical | 1 | 2021 | 677 | 0.120 |
Why?
| | Health Care Costs | 1 | 2020 | 425 | 0.120 |
Why?
| | Family Health | 1 | 2017 | 191 | 0.120 |
Why?
| | HLA-DQ Antigens | 1 | 2017 | 173 | 0.120 |
Why?
| | History, 21st Century | 1 | 2017 | 220 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2022 | 6399 | 0.120 |
Why?
| | Organelle Biogenesis | 1 | 2015 | 14 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2017 | 768 | 0.110 |
Why?
| | Subcutaneous Fat | 1 | 2015 | 79 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2017 | 267 | 0.110 |
Why?
| | Age of Onset | 1 | 2017 | 551 | 0.110 |
Why?
| | Proteins | 1 | 2021 | 1016 | 0.110 |
Why?
| | Genetic Testing | 1 | 2018 | 480 | 0.110 |
Why?
| | Hypoglycemia | 1 | 2020 | 479 | 0.110 |
Why?
| | Mass Screening | 2 | 2021 | 1348 | 0.110 |
Why?
| | Proteomics | 1 | 2021 | 1183 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1484 | 0.100 |
Why?
| | Gastric Bypass | 1 | 2015 | 126 | 0.100 |
Why?
| | Intestinal Mucosa | 1 | 2000 | 675 | 0.100 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 27 | 0.100 |
Why?
| | Body Mass Index | 2 | 2013 | 2419 | 0.100 |
Why?
| | Transcription Factors | 2 | 2015 | 1726 | 0.100 |
Why?
| | Adult | 8 | 2026 | 40489 | 0.090 |
Why?
| | Growth Disorders | 1 | 2013 | 86 | 0.090 |
Why?
| | Muscle Cells | 1 | 2013 | 41 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 3329 | 0.090 |
Why?
| | Aldehydes | 1 | 2013 | 141 | 0.090 |
Why?
| | Ultrasonography, Doppler | 1 | 2013 | 126 | 0.090 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 465 | 0.090 |
Why?
| | Human Growth Hormone | 1 | 2012 | 46 | 0.090 |
Why?
| | Models, Biological | 1 | 2019 | 1811 | 0.090 |
Why?
| | Colorado | 4 | 2026 | 4558 | 0.090 |
Why?
| | Glutathione | 1 | 2013 | 366 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.090 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2011 | 29 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 99 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2011 | 100 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2011 | 268 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1995 | 0.080 |
Why?
| | Diabetic Ketoacidosis | 2 | 2024 | 210 | 0.070 |
Why?
| | United States | 4 | 2022 | 16018 | 0.070 |
Why?
| | Time Factors | 2 | 2017 | 7140 | 0.070 |
Why?
| | Survivors | 1 | 2012 | 519 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1207 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1033 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2019 | 2117 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2015 | 2815 | 0.060 |
Why?
| | Genetic Association Studies | 2 | 2020 | 369 | 0.060 |
Why?
| | Obesity, Morbid | 1 | 2011 | 288 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2010 | 374 | 0.060 |
Why?
| | Overweight | 1 | 2011 | 606 | 0.060 |
Why?
| | Incidence | 2 | 2026 | 2892 | 0.060 |
Why?
| | Fatty Acid Transport Proteins | 3 | 1999 | 22 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5414 | 0.050 |
Why?
| | Risk Assessment | 3 | 2020 | 3729 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 176 | 0.050 |
Why?
| | C-Peptide | 1 | 2026 | 190 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 1076 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 81 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 161 | 0.050 |
Why?
| | Finland | 1 | 2022 | 78 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 171 | 0.050 |
Why?
| | Germany | 1 | 2022 | 138 | 0.050 |
Why?
| | Prognosis | 3 | 2018 | 4312 | 0.040 |
Why?
| | Mice | 3 | 2013 | 18261 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2021 | 54 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 44 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | Arachidonic Acid | 1 | 2021 | 101 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 53 | 0.040 |
Why?
| | Perception | 1 | 2023 | 376 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 83 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2021 | 55 | 0.040 |
Why?
| | Markov Chains | 1 | 2021 | 130 | 0.040 |
Why?
| | Animals | 5 | 2013 | 37948 | 0.040 |
Why?
| | Iodide Peroxidase | 1 | 2020 | 35 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 103 | 0.040 |
Why?
| | Glutens | 1 | 2020 | 60 | 0.040 |
Why?
| | Transfection | 2 | 1999 | 924 | 0.040 |
Why?
| | Absorption | 1 | 2000 | 61 | 0.040 |
Why?
| | Coenzyme A Ligases | 1 | 1999 | 15 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 167 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 122 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 62 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 590 | 0.040 |
Why?
| | Diffusion | 1 | 2000 | 124 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 184 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 214 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 281 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 282 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 221 | 0.040 |
Why?
| | Chromans | 1 | 1999 | 23 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 315 | 0.040 |
Why?
| | Retinoid X Receptors | 1 | 1999 | 38 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 1999 | 42 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 88 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 580 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 249 | 0.040 |
Why?
| | Oleic Acid | 1 | 1999 | 42 | 0.040 |
Why?
| | 3T3 Cells | 1 | 1999 | 156 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 481 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 190 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 418 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 672 | 0.030 |
Why?
| | Base Sequence | 2 | 1999 | 2177 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1998 | 93 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Nutritional Status | 1 | 2021 | 351 | 0.030 |
Why?
| | Thiazoles | 1 | 1999 | 139 | 0.030 |
Why?
| | Minority Groups | 1 | 2020 | 283 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 233 | 0.030 |
Why?
| | Tretinoin | 1 | 1999 | 124 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 252 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 565 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 133 | 0.030 |
Why?
| | Peer Group | 1 | 2020 | 256 | 0.030 |
Why?
| | Postmenopause | 1 | 2020 | 390 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2020 | 374 | 0.030 |
Why?
| | Universities | 1 | 2020 | 452 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1999 | 2909 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 450 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 618 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 167 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 638 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2873 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 441 | 0.030 |
Why?
| | Gestational Age | 1 | 2020 | 980 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 886 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 355 | 0.030 |
Why?
| | Nuclear Respiratory Factor 1 | 1 | 2015 | 3 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1122 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 39 | 0.030 |
Why?
| | Up-Regulation | 1 | 1999 | 848 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 890 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 650 | 0.030 |
Why?
| | Insulin Antibodies | 1 | 2016 | 103 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2015 | 62 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2021 | 771 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2839 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2018 | 420 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1569 | 0.030 |
Why?
| | Risk | 1 | 2018 | 911 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 669 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 381 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2015 | 234 | 0.030 |
Why?
| | Parents | 1 | 2023 | 1395 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1810 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1322 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2104 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 262 | 0.020 |
Why?
| | Family | 1 | 2018 | 685 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3414 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1537 | 0.020 |
Why?
| | DNA | 1 | 1999 | 1447 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 199 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 949 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1999 | 2037 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2026 | 11735 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 495 | 0.020 |
Why?
| | Minnesota | 1 | 2010 | 170 | 0.020 |
Why?
| | Middle Aged | 3 | 2020 | 35971 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 2045 | 0.020 |
Why?
| | Fatty Liver | 1 | 2009 | 250 | 0.020 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2009 | 180 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 578 | 0.010 |
Why?
| | Metabolic Syndrome | 1 | 2009 | 354 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1999 | 35 | 0.010 |
Why?
| | Aged | 1 | 2020 | 25955 | 0.010 |
Why?
| | COS Cells | 1 | 1999 | 177 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 535 | 0.010 |
Why?
| | Introns | 1 | 1998 | 255 | 0.010 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 1998 | 323 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1998 | 507 | 0.010 |
Why?
| | Exons | 1 | 1998 | 362 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1998 | 247 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 828 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1246 | 0.010 |
Why?
| | Protein Binding | 1 | 1998 | 2243 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 17149 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1998 | 1468 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2591 | 0.000 |
Why?
|
|
Frohnert's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|